RFP - Filgrastim Syringes or Biosimilar

Open Solicitation Posted

Solicitation number
36E79727R0001
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

The VA National Acquisition Center seeks offers for Filgrastim syringes in 300MCG (non-safety) or biosimilar and 480MCG (non-safety) or biosimilar formulations, with proposals due December 9, 2026 at 2:30 PM CST. The Set Aside line reads "No Set-Aside Used," and the notice states no sole-source intent or contract vehicle requirement. The attachment summary attributes issuance to the VA Enterprise Procurement Office, and the solicitation is issued under SF-1449 for commercial products and services. The NAICS code is 325412, Pharmaceutical Preparation Manufacturing, and the PSC is 6505, Drugs and Biologicals.

Estimated annual requirements are 22,665 syringes for the 300MCG line and 29,170 for the 480MCG line. Award will be made in the aggregate for both line items. The contract includes an implementation period of a maximum of 60 days or until June 29, 2027, followed by a one-year base ordering period and four optional one-year periods. Prices are required for the base year and all four option years, limited to two decimal places, and must include a 0.5% Cost Recovery Fee.

Government participants include all VA facilities, Department of Defense ordering activities, Indian Health Service facilities, Bureau of Prisons, Captain James A. Lovell Federal Health Care Center, and Option 2 State Veteran Homes. Products are distributed through Pharmaceutical Prime Vendor programs, with the VA PPV managed by McKesson Corporation and DoD PPVs managed by McKesson, Cencora, Cardinal Health, and DMS Pharmaceutical Group.

Offerors must provide a unique 11-digit NDC for each product, make all commercial package sizes available, and furnish FDA approval documentation confirming acceptable current Good Manufacturing Practices (cGMP) status for all manufacturing facilities. Distributors must submit Letters of Commitment from manufacturers. Products must comply with the Drug Supply Chain Security Act, including serialized transaction information using GS1 EPCIS standards and registration in the National Association of Boards of Pharmacy Trading Partner Directory. Covered drugs must meet Federal Ceiling Price limitations under 38 U.S.C. 8126. The contractor must maintain the same manufacturer and NDA/ANDA/BLA for the duration unless the Contracting Officer approves changes.

The attachments include a Small Business Subcontracting Plan template (08/2026) under FAR 52.219-9(d), with goal categories for SB, VOSB, SDVOSB, SDB, WOSB, and HUB.

Proposals must be submitted in Microsoft Word or PDF format by email to Dov Vysnia (dov.vysnia@va.gov) and Teresa Hussain (teresa.hussain@va.gov), with a scanned signed SF-1449. Faxed proposals will be rejected.

Notice text

See attached documents. 

Files

File Type Posted
SubcontractingPlan_Template_08_2026.pdf PDF
36E79727R0001.docx DOCX document

Notice history

Notice Type Posted
This notice Latest solicitation Solicitation
Filgrastim Biosimilar (VA-27-00012533) Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
Vancomycin hydrochlor and 1 more item Medical Supply Chain No set-aside
Syringe and needle, HY Medical Supply Chain No set-aside
Syringe, hypodermic Medical Supply Chain No set-aside
6505--VA Loma Linda FDG Department of Veterans Affairs VA Loma Linda Healthcare System Loma Linda CA 92357, United States · NAICS 325412 Veterans Integrated Service Network 22 No set-aside
6505--Nitroglycerin SL Tablets (VA-27-00011802) NAICS 325412 National Acquisition Center No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors